GlaxoSmithKline Stops Enrolling Patients in Feladilimab Cancer Trial
By Ian Walker
GlaxoSmithKline PLC said late Wednesday that it has stopped
enrolling patients in a trial studying a combination drug therapy
using feladilimab in cancer patients.
The pharmaceutical giant said it has decided to stop enrolling
patients in the Phase 2 Induce-3 trial following a recommendation
by the independent data monitoring committee. It has also decided
to stop the Induce-4 Phase 2 trial.
The Induce-3 trial was investigating feladilimab in combination
with pembrolizumab compared with a placebo in combination with
pembrolizumab in patients with PD-L1 positive recurrent locally
advanced or metastatic head and neck squamous cell carcinoma.
The Induce-4 trial was studying feladilimab compared with a
placebo in combination with pembrolizumab and chemotherapy.
Glaxo said the data taken so far will be used to assess the
impact on the overall clinical development program for
Write to Ian Walker at email@example.com
(END) Dow Jones Newswires
April 15, 2021 01:44 ET (05:44 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.